Reported Earlier, Adaptimmune's TECELRA Gains U.S. FDA Accelerated Approval As First Engineered Cell Therapy For Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Adaptimmune's TECELRA has received U.S. FDA accelerated approval as the first engineered cell therapy for solid tumors, specifically for advanced MAGE-A4+ synovial sarcoma in adults with certain HLA types who have received prior chemotherapy. This marks the first new treatment option for synovial sarcoma in over a decade.
August 02, 2024 | 7:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adaptimmune's TECELRA has received U.S. FDA accelerated approval, making it the first engineered cell therapy for solid tumors and the first new treatment for synovial sarcoma in over a decade.
The FDA's accelerated approval of TECELRA is a significant milestone for Adaptimmune, as it introduces the first engineered cell therapy for solid tumors and the first new treatment for synovial sarcoma in over a decade. This approval is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100